ALLIANCE UPDATE

Companies	Agreement
Aastrom Biosciences & Cobe	The two will commercialize Aastrom's Stem Cell Expansion System, focusing on bone-marrow and stem-cell transplantation resulting from high-dose chemotherapy, with an aim of transforming these transplants from acute-care procedures into simplified procedures that can be handled on an outpatient basis. Cobe has made a \$10 million equity investment in Aastrom and will provide a further \$10 million based on certain milestones.
Affinity Biotech & Bio-Pharm Clinical Services	Bio-Pharm will merge into Affinity in a transaction that values Bio-Pharm at about \$25 million. The resultant company will combine Affinity's abilities to help pharmaceutical firms develop improved formulations of existing drugs with Bio-Pharm's abilities to conduct clinical trials.
Bio-Technology General & Societa Prodottie Antibiotici	Societa Prodottie Antibiotici will manufacture Bio-Technology General's (BTG) Oxandrin (oxandrolone) for both firms and market the product in the countries of Western Europe, Eastern Europe, and the former Soviet Union. BTG is developing Oxandrin for use in pediatric growth disorders, certain conditions suffered by AIDS patients, and alcoholic hepatitis.
Boron Biologicals & Guerbet	Expanding on an earlier licensing agreement, Guerbet has made a substantial equity investment in Boron. The earlier agreement calls for Boron to design new contrast agents for X-ray imaging. Guerbet then provides clinical testing and receives exclusive marketing rights to the agents.
Celgene & Betz Laboratories	The two announced that their strategic alliance, formed in January 1993, will end on January 12. The agreement, which had an optional four-year extension, provided for Betz to commercialize Celgene's biotreatment-systems technology for reducing pollutants in industrial process streams.
CellPro & Corange	Corange will invest \$110 million in CellPro through the purchase of CellPro common stock and will make payments to CellPro that could total as much as \$55 million in research-and-development funding and a further \$45 million in milestone payments, as well as a \$10 million signing fee. The two will jointly develop and market CellPro's stem-cell-selection products for therapeutic applications outside the U.S. and Canada and share profits. Corange will acquire exclusive worldwide rights to diagnostic products using CellPro's cell-selection technology.
Enzon & Cell Genesys	Cell Genesys will use Enzon's Single-Chain Antigen-Binding (SCA) technology in conjunction with its universal-receptor technology. Enzon's SCA proteins provide the binding specificity of monoclonal antibodies but in a smaller form. Cell Genesys' universal-receptor technology involves the genetic modification of T cells with novel cell-surface receptors that allow these T cells to recognize specific disease targets in multiple patients with that disease.
Genzyme & Pasteur Merieux	Pasteur Merieux—which extracts from placenta the source material, glucocerebrosidase (GCR), for the production of Genzyme's Ceredase—will stop production of human albumin from placenta in response to a French government directive to implement additional control procedures relating to the preparation of placental-based albumin. This may result in an increase in GCR's annual production costs of up to \$22 million at current production levels. It is uncertain to what extent these costs will be reflected in Ceredase's already astronomical price of about \$140,000 per patient.
Immunex & American Cyanamid	American Cyanamid, which currently owns 53.5 percent of Immunex's common stock, has notified Immunex that it may make open market purchases of Immunex common stock. Cyanamid can increase its ownership of Immunex up to 70 percent of the firm's outstanding common stock.
Ligand Pharmaceuticals & Allergan	The two have filed their joint venture's first investigational-new-drug application for the use of 9- <i>cis</i> -retinoic acid (LGD1057), to be given orally for cancer therapy. LGD1057 inhibits cell proliferation and induces programmed cell death and cell differentiation, which could be useful against certain leukemias and squamous cell carcinomas.
Ligand Pharmaceuticals & Pfizer	The firms' strategic alliance—initiated in 1991 in the area of intracellular-receptor technology—has yielded a drug-development candidate, and potential back-up candidates, for osteoporosis. Pfizer intends to take the first of these compounds through preclinical development and into clinical trials by 1995.
Phytara & Amersham	The two will develop novel enzymes derived from Phytara's plant-cell-culture library. Amersham will market products worldwide for the research market. The two will share rights to products for the international clinical-diagnostic market.
Receptagen & Ryan Pharmaceuticals	Receptagen has executed a share-exchange agreement with Ryan to make Ryan a wholly owned subsidiary of Receptagen. Ryan owns the exclusive U.S. patent rights to Coenzyme Q10, a naturally occurring compound that is approved in Japan for congestive heart failure and is in U.S. phase I trials in AIDS patients as an immune stimulant.
United States Biochemical & Roche Molecular Systems	To accelerate the development of PCR applications, Roche has granted a license to United States Biochemical giving it worldwide rights to manufacture and sell <i>Taq</i> DNA polymerase and other thermostable enzymes and products in the research market for use in the PCR process.

AGBIOTECH

DNA Plant Technology & Du Pont	DNA Plant Technology (DNAP) will acquire Du Pont's ownership interest in FreshWorld, a premium fruit and vegetable business that, until now, has been a 50/50 joint venture with Du Pont. In exchange, DNAP will give Du Pont its 28 percent minority interest in Intermountain Canola, another DNAP/Du Pont joint venture, as well as the equivalent of 4.75 million shares of DNAP common stock and rights to other DNAP technologies and assets. DNAP hopes to evolve from a startup company that relies on joint ventures to a fully integrated firm focusing on fresh and processed fruits and vegetables.
--------------------------------	---

—Mark Goodstein